BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38422823)

  • 1. Uncovering PPAR-γ agonists: An integrated computational approach driven by machine learning.
    Haider S; Shafiq M; Siddiqui AR; Sardar M; Mushtaq M; Shafeeq S; Nur-E-Alam M; Ahmad A; Ul-Haq Z
    J Mol Graph Model; 2024 Jun; 129():108742. PubMed ID: 38422823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
    Najmi A; Alam MS; Thangavel N; Taha MME; Meraya AM; Albratty M; Alhazmi HA; Ahsan W; Haque A; Azam F
    Sci Rep; 2023 Nov; 13(1):19869. PubMed ID: 37963936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
    Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
    J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.
    Álvarez-Almazán S; Bello M; Tamay-Cach F; Martínez-Archundia M; Alemán-González-Duhart D; Correa-Basurto J; Mendieta-Wejebe JE
    Biochem Pharmacol; 2017 Oct; 142():168-193. PubMed ID: 28716729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
    Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
    J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
    Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
    PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico approach for the discovery of new PPARγ modulators among plant-derived polyphenols.
    Encinar JA; Fernández-Ballester G; Galiano-Ibarra V; Micol V
    Drug Des Devel Ther; 2015; 9():5877-95. PubMed ID: 26604687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
    Mandal S; Faizan S; Raghavendra NM; Kumar BRP
    Mol Divers; 2023 Dec; 27(6):2605-2631. PubMed ID: 36437421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INT131: a selective modulator of PPAR gamma.
    Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
    J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ.
    Almahmoud S; Zhong HA
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-γ agonists as anti-diabetic drugs.
    Ahmed S; Islam N; Shahinozzaman M; Fakayode SO; Afrin N; Halim MA
    J Biomol Struct Dyn; 2021 Feb; 39(2):728-742. PubMed ID: 31916505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
    Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
    Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.
    Gee VM; Wong FS; Ramachandran L; Sethi G; Kumar AP; Yap CW
    J Comput Aided Mol Des; 2014 Nov; 28(11):1143-51. PubMed ID: 25168706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
    Nath V; Agrawal R; Kumar V
    J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay.
    Li Y; Ks N; Byran G; Krishnamurthy PT
    Appl Biochem Biotechnol; 2023 Feb; 195(2):1014-1041. PubMed ID: 36264481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
    Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA
    J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
    Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
    J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.